Gilead Sciences (GILD) Dividend Coverage Ratio Growth (3y) (2018 - 2026)
Analysis
Gilead Sciences (GILD) Dividend Coverage Ratio Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 12.93% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -124.72% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.99 Bn | 26.83 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -124.72% |
| Mar 31, 2026 | 24.15% |
| Dec 31, 2025 | 13.06% |
| Sep 30, 2025 | 17.02% |
| Jun 30, 2025 | 17.33% |
| Mar 31, 2025 | 368.04% |
| Dec 31, 2024 | 63.90% |
| Sep 30, 2024 | -23.44% |
| Jun 30, 2024 | -0.57% |
| Mar 31, 2024 | -61.90% |
| Dec 31, 2023 | -5.77% |
| Sep 30, 2023 | 77.49% |
| Jun 30, 2023 | 31.65% |
| Mar 31, 2023 | -16.75% |
| Dec 31, 2022 | 26.58% |
| Sep 30, 2022 | 49.22% |
| Jun 30, 2022 | -19.27% |
| Mar 31, 2022 | -82.60% |
| Dec 31, 2021 | -10.37% |
| Sep 30, 2021 | 0.52% |